Compare Incyte Corporation (INCY) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Philip Morris International Inc. — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Philip Morris International Inc. trades at $191.86 (market cap $300.37B). The key difference: Philip Morris International Inc. is far larger — about 13× Incyte Corporation's market cap, and Philip Morris International Inc. pays a 3.05% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PM | |
|---|---|---|
Market Cap | $23.11B | $300.37B |
Sector | Health | Consumer Staples |
52-Week High | $118.52 | $192.98 |
52-Week Low | $67.38 | $144.33 |
Enterprise Value | $19.13B | $346.86B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Philip Morris International (PM) trades at $192.72, down 0.13% on the day, with a bullish technical signal and strong analyst consensus. Recent financials show robust revenue growth to $40.65B in 2025 and net income of $11.35B, though a Q4 2025 earnings miss and a recent $500M impairment charge highlight near-term pressures. The stock's P/E of 27.17 and P/S of 7.25 reflect premium valuation, supported by a 68% buy rating from analysts and a $194.00 consensus price target.
Outlook remains positive with steady cash flow and dividend payments, but risks include regulatory challenges from rising illicit cigarette trade in Europe and cost pressures. The stock offers stability through high margins and brand strength, yet investors should weigh valuation against earnings volatility and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
